Format
Sort by

Send to

Choose Destination

Search results

Items: 18

1.

Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey.

Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group.

J Int AIDS Soc. 2016 Jan 8;19(1):20095. doi: 10.7448/IAS.19.1.20095. eCollection 2016.

2.

Sub-Saharan African migrants living with HIV acquired after migration, France, ANRS PARCOURS study, 2012 to 2013.

Desgrées-du-Loû A, Pannetier J, Ravalihasy A, Gosselin A, Supervie V, Panjo H, Bajos N, Lert F, Lydié N, Dray-Spira R; Parcours Study Group5.

Euro Surveill. 2015;20(46). doi: 10.2807/1560-7917.ES.2015.20.46.30065. Erratum in: Euro Surveill. 2015;20(47). doi: 10.2807/1560-7917.ES.2015.20.47.30069.

PMID:
26607135
3.

Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).

Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836. No abstract available.

PMID:
26569181
4.

Is hardship during migration a determinant of HIV infection? Results from the ANRS PARCOURS study of sub-Saharan African migrants in France.

Desgrees-du-Lou A, Pannetier J, Ravalihasy A, Le Guen M, Gosselin A, Panjo H, Bajos N, Lydie N, Lert F, Dray-Spira R; PARCOURS Study Group.

AIDS. 2016 Feb 20;30(4):645-56. doi: 10.1097/QAD.0000000000000957.

5.

Has the employment status of people living with HIV changed since the early 2000s?

Annequin M, Lert F, Spire B, Dray-Spira R; VESPA2 Study Group.

AIDS. 2015 Jul 31;29(12):1537-47. doi: 10.1097/QAD.0000000000000722.

PMID:
26244393
6.

Women living with HIV still lack highly effective contraception: results from the ANRS VESPA2 study, France, 2011.

Maraux B, Hamelin C, Bajos N, Dray-Spira R, Spire B, Lert F; Vespa2 study group.

Contraception. 2015 Aug;92(2):160-9. doi: 10.1016/j.contraception.2015.04.010. Epub 2015 May 2.

PMID:
25940932
7.

Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).

Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914. Epub 2015 Feb 27.

PMID:
25723557
8.

Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).

Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

AIDS Care. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553. Epub 2014 Apr 14.

PMID:
24731158
9.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F; French ANRS HIV-2 CO5 Cohort.

Clin Infect Dis. 2012 Nov 15;55(10):1417-25. doi: 10.1093/cid/cis708. Epub 2012 Aug 20.

10.

X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI.

Ghosn J, Galimand J, Raymond S, Meyer L, Deveau C, Goujard C, Izopet J, Rouzioux C, Chaix ML; ANRS CO 06 PRIMO cohort.

PLoS One. 2011;6(8):e23301. doi: 10.1371/journal.pone.0023301. Epub 2011 Aug 24.

11.

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group.

HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13.

12.

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group.

Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18.

13.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.

Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups.

AIDS. 2009 Mar 27;23(6):717-24. doi: 10.1097/QAD.0b013e328326ca77.

PMID:
19279445
14.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20.

15.

Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.

Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team.

HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8.

16.

Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring.

Gasnault J, Kousignian P, Kahraman M, Rahoiljaon J, Matheron S, Delfraissy JF, Taoufik Y.

J Neurovirol. 2001 Aug;7(4):375-81.

PMID:
11517420
18.

Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy.

Gasnault J, Taoufik Y, Goujard C, Kousignian P, Abbed K, Boue F, Dussaix E, Delfraissy JF.

J Neurovirol. 1999 Aug;5(4):421-9.

PMID:
10463864
Items per page

Supplemental Content

Loading ...
Write to the Help Desk